☆ 4.6 Article

89Zr-Immuno-PET with Immune Checkpoint Inhibitors: Measuring Target Engagement in Healthy Organs

CANCERS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Radiology, Nuclear Medicine & Medical Imaging

89Zr-immuno-PET using the anti-LAG-3 tracer [89Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC

Iris H. C. Miedema et al.

Summary: This study explored the potential use of the anti-LAG-3 antibody tracer [Zr-89]Zr-BI 754111 as a predictive imaging biomarker and investigated its target specific uptake as well as the correlation of its tumor uptake and the tumor immune infiltration. The results showed that [Zr-89]Zr-BI 754111 PET imaging has favorable technical and biological characteristics for developing a potential predictive imaging biomarker for LAG-3-directed therapies.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2023)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Validation of simplified uptake measures against dynamic Patlak Ki for quantification of lesional 89Zr-Immuno-PET antibody uptake

Jessica E. Wijngaarden et al.

Summary: This study assesses the validity of three commonly used quantification parameters (SUV, TPR, and TBR) in quantifying reversible Zr-89-Immuno-PET uptake. The results showed that SUV, TPR, and TBR are valid quantification parameters for constant mass doses. However, for variable mass doses, only TPR and TBR provide reliable quantification values, while SUV does not consider patient and mass dose-specific plasma clearance.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2023)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Study of 89Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Non-Small Cell Lung Cancer

Anna-Larissa N. Niemeijer et al.

Summary: This study investigated the response of NSCLC patients to pembrolizumab monotherapy and the uptake of Zr-89-pembrolizumab in tumors, finding that patients with higher uptake had better responses to treatment. Although no significant correlation was found with PD-L1 or PD-1 immunohistochemistry, the injection of Zr-89-pembrolizumab was deemed safe in the study.

JOURNAL OF NUCLEAR MEDICINE (2022)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

89Zr-DFO-Durvalumab PET/CT Before Durvalumab Treatment in Patients with Recurrent or Metastatic Head and Neck Cancer

Sarah R. Verhoeff et al.

Summary: In this study, we used 89Zr-DFO-durvalumab PET/CT to predict the treatment response of durvalumab in patients with squamous cell carcinoma of the head and neck. We found that 89Zr-DFO-durvalumab uptake was correlated with tumor PD-L1 expression and 18F-FDG uptake, but it could not predict treatment response.

JOURNAL OF NUCLEAR MEDICINE (2022)

添加到收藏夹

Review Medicine, General & Internal

ImmunoPET: Antibody-Based PET Imaging in Solid Tumors

Reyhaneh Manafi-Farid et al.

Summary: Immuno-positron emission tomography (immunoPET) is a molecular imaging technique that combines the high sensitivity of PET with the targeted ability of monoclonal antibodies. While various radioimmunotracers have been developed, only a few have been translated into clinical practice due to issues such as slow kinetics, high physiological uptake, and heterogeneous activity. Efforts are being made to overcome these limitations and develop new tracers.

FRONTIERS IN MEDICINE (2022)

添加到收藏夹

Article Oncology

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

Martin Reck et al.

Summary: This study reports the first 5-year follow-up of a first-line immunotherapy trial for NSCLC, demonstrating that pembrolizumab provides a durable, clinically meaningful long-term overall survival benefit in first-line treatment of metastatic NSCLC with a PD-L1 tumor proportion score of at least 50%.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Immuno-PET Imaging to Assess Target Engagement: Experience from 89Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors

C. Willemien Menke-van der Houven van Oordt et al.

JOURNAL OF NUCLEAR MEDICINE (2019)

添加到收藏夹

Article Oncology

Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma

Jacob H. Rasmussen et al.

BRITISH JOURNAL OF CANCER (2019)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

89Zr-Immuno-PET: Toward a Noninvasive Clinical Tool to Measure Target Engagement of Therapeutic Antibodies In Vivo

Yvonne W. S. Jauw et al.

JOURNAL OF NUCLEAR MEDICINE (2019)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness et al.

LANCET (2019)

添加到收藏夹

Meeting Abstract Oncology

Tumor uptake and biodistribution of 89Zirconium-labeled ipilimumab in patients with metastatic melanoma during ipilimumab treatment

Iris H. Miedema et al.

CANCER RESEARCH (2019)

添加到收藏夹

Article Biochemical Research Methods

Multiplex Immuno-Liquid Chromatography-Mass Spectrometry-Parallel Reaction Monitoring (LC-MS-PRM) Quantitation of CD8A, CD4, LAG3, PD1, PD-L1, and PD-L2 in Frozen Human Tissues

Qian Zhang et al.

JOURNAL OF PROTEOME RESEARCH (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Zr-89-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer

Frederike Bensch et al.

NATURE MEDICINE (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer

A. N. Niemeijer et al.

NATURE COMMUNICATIONS (2018)

添加到收藏夹

Review Biochemistry & Molecular Biology

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Padmanee Sharma et al.

CELL (2017)

添加到收藏夹

Article Oncology

Antibody Positron Emission Tomography Imaging in Anticancer Drug Development

Laetitia E. Lamberts et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer

Edward B. Garon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

H. Borghaei et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Medicine, General & Internal

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

J. Larkin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Editorial Material Radiology, Nuclear Medicine & Medical Imaging

Immuno-PET of Cancer: A Revival of Antibody Imaging

Otto C. Boerman et al.

JOURNAL OF NUCLEAR MEDICINE (2011)

添加到收藏夹

Review Medicine, Research & Experimental

Monoclonal antibodies in neuro-oncology Getting past the blood-brain barrier

Lois A. Lampson

MABS (2011)

添加到收藏夹

Article Immunology

Differential subcellular localization of the regulatory T-cell protein LAG-3 and the coreceptor CD4

Seng-Ryong Woo et al.

EUROPEAN JOURNAL OF IMMUNOLOGY (2010)

添加到收藏夹

Letter Biotechnology & Applied Microbiology

Towards a knowledge-based Human Protein Atlas

Mathias Uhlen et al.

NATURE BIOTECHNOLOGY (2010)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Radiation Dosimetry of 89Zr-Labeled Chimeric Monoclonal Antibody U36 as Used for Immuno-PET in Head and Neck Cancer Patients

Pontus K. E. Boerjesson et al.

JOURNAL OF NUCLEAR MEDICINE (2009)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

How should we analyse FDG PET studies for monitoring tumour response?

Adriaan A. Lammertsma et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2006)

添加到收藏夹

Review Chemistry, Medicinal

Antibody pharmacokinetics and pharmacodynamics

ED Lobo et al.

JOURNAL OF PHARMACEUTICAL SCIENCES (2004)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.